What is Semax & Selank?
Semax is an ACTH-derived peptide analogue investigated in neurological and neuroprotective contexts. Selank is a synthetic peptide related to tuftsin and has been studied particularly in anxiety disorders. They should be evaluated separately despite being grouped together online.
Proposed mechanism
Semax research has explored neurotrophic, melanocortin-related and gene-expression effects. Selank research has examined GABAergic, enkephalin and anxiety-related pathways. Neither mechanism converts automatically into proven cognitive enhancement in healthy people.
What has been published?
Published human studies exist, including Russian-language clinical trials. Selank has comparative anxiety studies, while Semax has been studied in neurological and other clinical contexts. Much of the evidence base is regional and older.
Current human evidence
The existence of human studies makes these peptides different from purely preclinical compounds, but the international evidence base is still limited by study size, replication, reporting standards and limited independent confirmation.
Regulatory status
Neither Semax nor Selank is an FDA-approved drug in the United States, and they do not have broad approval across major Western regulators.
Possible areas of research interest
- Anxiety research
- Neuroprotection
- Cognition and attention
- Peptide neuromodulation
Important limitations
- Evidence is geographically concentrated
- Many trials are small or older
- Healthy-user enhancement claims are not established
- Long-term comparative safety data are limited
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.